Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trialThe aim of the present study was to assess the efficacy and safety of teneligliptin in combination with metformin in Korean patients with type 2 diabetes mellitus who were inadequately controlled with metformin monotherapy. Patients [glycated haemoglobin (HbA1c) 7.0-10.0%, on stable metformin ≥1000 mg/day] were randomized 2 : 1 to receive 20 mg teneligliptin plus metformin (n = 136) or placebo plus metformin (n = 68). The primary endpoint was the change in HbA1c levels from baseline to week 16. The mean baseline HbA1c was 7.9% in the teneligliptin group and 7.8% in the placebo group. The differences between the teneligliptin and placebo groups regarding changes in HbA1c and fasting plasma glucose levels were −0.78 % and −1.24 mmol/l (22.42 mg/dl), respectively, at week 16. The incidence of adverse events was similar between the groups. The addition of teneligliptin once daily to metformin was effective and generally well tolerated in Korean patients with type 2 diabetes.

We conducted a 24-week, multicentre, double-blind, randomized study with a 28-week extension to compare the efficacy and safety of anagliptin and sitagliptin as an add-on to metformin in patients with type 2 diabetes. Patients inadequately controlled on metformin were randomized to either anagliptin (100 mg twice daily, n = 92) or sitagliptin (100 mg once daily, n = 88). The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline to week 24. The mean changes in HbA1c were -0.85 ± 0.70% (p < 0.0001) for anagliptin and -0.83 ± 0.61% (p < 0.0001) for sitagliptin, with a mean difference of -0.02% (95% confidence interval of difference, -0.22 to 0.18%). In both groups, the fasting proinsulin : insulin ratio significantly decreased from baseline, with improved insulin secretion. Safety profiles were similar in each group. In conclusion, the non-inferiority of the efficacy of anagliptin to sitagliptin as an add-on therapy was established with regard to efficacy and safety.

No abstract

ГИДРО-И ОЛЕОФОБНЫЕ ПОКРЫТИЯ НА ОСНОВЕ ПОЛИВИНИЛОВОГО СПИРТА И НАНОЧАСТИЦ ДИОКСИДА КРЕМНИЯ Аннотация. Изучена смачиваемость композиционных покрытий на основе поливинилового спирта (ПВС) и диоксида кремния, сформированных на кремнии методом центрифугирования из коллоидов наночастиц SiO 2 в ПВС. Установлено, что данные покрытия, модифицированные гидролизованным гептадекафтортетрагидродецилтриметоксисиланом, проявляют супергидрофобные и олеофобные свойства. Показано, что ПВС увеличивает стабильность покрытий SiO 2-ПВС к механическому воздействию. Ключевые слова: наночастицы оксида кремния, поливиниловый спирт, супергидрофобные покрытия, фторсиланы, олеофобность Для цитирования: Гидро-и олеофобные покрытия на основе поливинилового спирта и наночастиц диоксида кремния / А. Е. Соломянский [и др.] // Докл.